NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $7.98 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.97 -0.01 (-0.13%) As of 05/22/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CorMedix Stock (NASDAQ:CRMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CorMedix alerts:Sign Up Key Stats Today's Range$7.97▼$8.1450-Day Range$6.25▼$8.0652-Week Range$6.13▼$17.43Volume825,789 shsAverage Volume1.40 million shsMarket Capitalization$626.05 millionP/E Ratio3.75Dividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company Overview CorMedix Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers. In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures. The company is engaged in clinical and regulatory activities designed to support product labeling updates and broader patient access. Collaborative partnerships with dialysis providers and distributors help position CorMedix to deliver its therapies into established treatment settings. Founded in the mid-2000s and headquartered in Piscataway, New Jersey, CorMedix operates with a lean corporate structure that leverages external manufacturing and distribution networks. The company’s senior management team is led by President and Chief Executive Officer Craig Fraser, who brings more than 30 years of experience in the biopharmaceutical industry. CorMedix continues to pursue regulatory milestones and commercial arrangements that aim to expand its reach across North America, Europe and select emerging markets.AI Generated. May Contain Errors. Read More CorMedix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreCRMD MarketRank™: CorMedix scored higher than 64% of companies evaluated by MarketBeat, and ranked 266th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCorMedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialCorMedix has a consensus price target of $15.00, representing about 88.0% upside from its current price of $7.98.Amount of Analyst CoverageCorMedix has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CorMedix's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-68.09% Earnings GrowthEarnings for CorMedix are expected to decrease by -68.09% in the coming year, from $0.47 to $0.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is 3.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is 3.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.01.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.43% of the float of CorMedix has been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 16.64, which indicates bearish sentiment.Change versus previous monthShort interest in CorMedix has recently increased by 3.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.81 News SentimentCorMedix has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CorMedix this week, compared to 6 articles on an average week.Search Interest32 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 113% compared to the previous 30 days.MarketBeat Follows8 people have added CorMedix to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by Insiders3.50% of the stock of CorMedix is held by insiders.Percentage Held by Institutions34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRMD Stock News HeadlinesCorMedix: Long-Term Prospects Remain Poor Despite Q1 BeatMay 18, 2026 | seekingalpha.comDoes Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)?May 18, 2026 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 25 at 1:00 AM | InvestorPlace (Ad)A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year GuidanceMay 16, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Cormedix (CRMD)May 15, 2026 | theglobeandmail.comCormedix Therapeutics to Participate in two Upcoming Investor ConferencesMay 15, 2026 | globenewswire.comCormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 15, 2026 | finance.yahoo.comCRMD stock soared 18% today – here’s what fueled CorMedix’s triple-digit Q1 revenue surgeMay 14, 2026 | msn.comSee More Headlines CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $11.63 on January 1st, 2026. Since then, CRMD shares have decreased by 31.4% and is now trading at $7.98. How were CorMedix's earnings last quarter? CorMedix Inc (NASDAQ:CRMD) released its quarterly earnings data on Thursday, May, 14th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.35 by $0.08. The company's quarterly revenue was up 226.1% compared to the same quarter last year. Read the conference call transcript. When did CorMedix's stock split? CorMedix's stock reverse split before market open on Tuesday, March 26th 2019.The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Is CorMedix doing a stock buyback? CorMedix's Board of Directors authorized a stock buyback plan on Monday, February 2nd 2026, which allows the company to buy back $75,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 12.3% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its shares are undervalued. Who are CorMedix's major shareholders? Top institutional investors of CorMedix include Private Advisor Group LLC (0.64%), Bank of New York Mellon Corp (0.47%), Empowered Funds LLC (0.34%) and Lazard Asset Management LLC (0.31%). Insiders that own company stock include Joseph Todisco, Myron Kaplan, Kaufman Beth Zelnick, Elizabeth Hurlburt, Steven W Lefkowitz, Erin Mistry and Alan W Dunton. View institutional ownership trends. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), AUO (AUOTY), The RMR Group (RMR). Company Calendar Last Earnings5/14/2026Today5/25/2026Jefferies Global Healthcare Conference 20266/03/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CRMD's financial health is in the Red zone, according to TradeSmith. CRMD has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRMD CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees30Year Founded2006Price Target and Rating Average Price Target for CorMedix$15.00 High Price Target$19.00 Low Price Target$13.00 Potential Upside/Downside+88.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$2.13 Trailing P/E Ratio3.75 Forward P/E Ratio16.98 P/E GrowthN/ANet Income$163.05 million Net Margins45.25% Pretax Margin46.25% Return on Equity45.57% Return on Assets24.76% Debt Debt-to-Equity Ratio0.33 Current Ratio2.97 Quick Ratio2.74 Sales & Book Value Annual Sales$400.05 million Price / Sales1.56 Cash Flow$2.05 per share Price / Cash Flow3.90 Book Value$5.57 per share Price / Book1.43Miscellaneous Outstanding Shares78,452,000Free Float75,706,000Market Cap$626.05 million OptionableOptionable Beta1.46 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CRMD) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
